These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18477208)

  • 21. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen levels and sex functions in testosterone-treated hypogonadal men.
    Gooren LJ
    Arch Sex Behav; 1987 Dec; 16(6):463-73. PubMed ID: 3426390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hypogonadism and cardiovascular diseases in men].
    Ter Arkh; 2011; 83(10):61-7. PubMed ID: 22185029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
    Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
    Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Androgen replacement therapy in late-onset hypogonadism: current concepts and controversies - a mini-review.
    Mäkinen JI; Huhtaniemi I
    Gerontology; 2011; 57(3):193-202. PubMed ID: 20689266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies.
    Behre HM; Abshagen K; Oettel M; Hübler D; Nieschlag E
    Eur J Endocrinol; 1999 May; 140(5):414-9. PubMed ID: 10229906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen replacement therapy: present and future.
    Gooren LJ; Bunck MC
    Drugs; 2004; 64(17):1861-91. PubMed ID: 15329035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unexpectedly prolonged washout period of exogenous testosterone after discontinuation of intramuscular testosterone undecanoate depot injection (Nebido(®) or Reandron(®) ) in men with congenital hypogonadotrophic hypogonadism.
    Gan EH; Bouloux PM; Quinton R
    Clin Endocrinol (Oxf); 2016 Jun; 84(6):947-50. PubMed ID: 26732131
    [No Abstract]   [Full Text] [Related]  

  • 29. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism.
    Harle L; Basaria S; Dobs AS
    Expert Opin Pharmacother; 2005 Aug; 6(10):1751-9. PubMed ID: 16086661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Testosterone depot injection in male hypogonadism: a critical appraisal.
    Yassin AA; Haffejee M
    Clin Interv Aging; 2007; 2(4):577-90. PubMed ID: 18225458
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of testosterone replacement therapy in men.
    Winters SJ
    Arch Fam Med; 1999; 8(3):257-63. PubMed ID: 10333822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9-12 February 2006, Salzburg, Austria.
    Morales A; Nieschlag E; Schubert M; Yassin AA; Zitzmann M; Oettel M
    Aging Male; 2006 Dec; 9(4):221-7. PubMed ID: 17178558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testosterone undecanoate: a new orally active androgen.
    Hirschhäuser C; Hopkinson CR; Sturm G; Coert A
    Acta Endocrinol (Copenh); 1975 Sep; 80(1):179-87. PubMed ID: 1098350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous and exogenous testosterone levels after administration of deuterium-labelled testosterone propionate in hypogonadotropic hypogonadism.
    Fujioka M; Shinohara Y; Baba S; Irie M; Inoue K
    Chem Pharm Bull (Tokyo); 1989 Nov; 37(11):3100-1. PubMed ID: 2632058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endocrinology Update: Testicular Hypogonadism.
    Heidelbaugh JJ
    FP Essent; 2016 Dec; 451():31-41. PubMed ID: 27936533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical use of androgens.
    Snyder PJ
    Annu Rev Med; 1984; 35():207-17. PubMed ID: 6372655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of testosterone undecanoate in male hypogonadism.
    Maisey NM; Bingham J; Marks V; English J; Chakraborty J
    Clin Endocrinol (Oxf); 1981 Jun; 14(6):625-9. PubMed ID: 7296909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in testosterone replacement therapy.
    Gooren L
    Front Horm Res; 2009; 37():32-51. PubMed ID: 19011287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen-behavior correlations in hypogonadal men and eugonadal men. I. Mood and response to auditory sexual stimuli.
    Alexander GM; Swerdloff RS; Wang C; Davidson T; McDonald V; Steiner B; Hines M
    Horm Behav; 1997 Apr; 31(2):110-9. PubMed ID: 9154431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone replacement treatment options for HIV-infected men.
    Cofrancesco J; Whalen JJ; Dobs AS
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Dec; 16(4):254-65. PubMed ID: 9402072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.